About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, March 26th, 2013

The QualityStocks
Daily Stock List


Lion Gold Brazil, Inc. (LGBI)

UndiscoveredEquities reported earlier on Lion Gold Brazil, Inc. (LGBI), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Trading on the OTC Pink Current Information, Lion Gold Brazil, Inc. is a leader in gold exploration and exploitation in Brazil. The Company focuses on discovering and advancing gold properties. They are continually looking to add highly promising projects to their asset property base through acquiring additional leases, or by entering into Joint Venture agreements that will add to overall shareholder value.

A Nevada Corporation, Lion Gold Brazil has their headquarters in Barra da Tijuca, Rio de Janeiro, Brazil. The Company in the past went by the name Rebuilder Medical Technologies, Inc. They changed their name to Lion Gold Brazil, Inc. in August of 2012.

In December of 2012, the Company reviewed numerous properties, which have alluvial gold deposits, as possible candidates for their special Quad Mining Model. One of them (Tapajos region) had test results of 0.68-0.75 grams of gold per ton with a range of 0.46 grams to 1.55 grams per ton; the preliminary estimates of the reserve are approximately 450,000 ounces. 

These testings results have to undergo validation before moving forward. According to Lion Gold Brazil's expert geologist, Antonio de Castro, deposit of this size can undergo mining in at a rate of 30,000 ounces per year, per plant. These internal numbers indicate a potential for mining the property for a minimum of 10 years.

Last month, Lion Gold Brazil announced that they started negotiations with Chinese gold plant manufacturer, Shanghai Firstmining Machinery Co., Ltd., for their special prototype mobile plant destined for use in several of Lion Gold Brazil's gold mining locations, using Lion Gold Brazil's unique and proprietary Quad Mining model operational approach. The Company engaged Firstmining in order to design the first Quad Project prototype plant that includes the three stage processing (Gravimetry, Floatation and Leaching), all housed in one mobile unit. This unit will process primarily low-grade tailings ore. Shanghai Firstmining Machinery specializes in supplying and exporting all types of mining equipment.

Lion Gold Brazil, Inc. (LGBI), closed Monday's trading session at $0.0002, up 100.00%, on 3,000,000 volume with 1 trade. The stock's 52-week low/high is $0.0001/$0.035.

Wavefront Technology Solutions, Inc. (WFTSF)

SmarTrend Newsletters and IRGnews Alert reported earlier on Wavefront Technology Solutions, Inc. (WFTSF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Wavefront Technology Solutions, Inc. is a developer of leading-edge technology for fluid injection optimization for improved performance and profitability in the oil and gas and environmental sectors. The Company's vigorous injection approach is suited for oil recovery revitalization and in the cleanup of shallow ground contamination. Wavefront specializes in designing solutions for oil well stimulation, secondary oil recovery, as well as environmental groundwater remediation. Wavefront Technology Solutions lists on the OTCQX International.

The Company works to gain recognition as an international leader of fluid injection technologies that maximize reservoir recovery, drilling efficiency, and groundwater restoration. Wavefront deploys their oil production improvement technique (their Powerwave process) in their fields. Wavefront collaborates with other producers; they provide site-specific licensing agreements to major oil producers. The Company has 20 granted and 29 patents pending based on differentiated fluid flow technology.

Their business plan includes licensing of their proprietary technologies and products, underpinned by a high margin recurring revenue model. Their business plan additionally includes leveraging of their proprietary technologies and products by way of strategic service company alliances in the energy and environmental sectors.

Wavefront markets their process as Powerwave and Primawave. Their patented Powerwave process is an injection technology that improves the flow of fluids in geological materials. This includes sedimentary soils and fractured rock. Powerwave works to improve oil recovery through optimizing the performance of existing methods including chemical EOR technologies, liquid CO2 injection, water injection, and surfactant/polymer flooding.

In addition, the Company's Primawave process is an effective method for aiding in-situ (in-ground) environmental groundwater remediation clean-up strategies in contaminated sites. Primawave is applicable to a vast percentage of all contaminated sites. It has verification as an effective environmental remedial strategy by Environment and Industry Canada.

Recently, Wavefront Technology Solutions announced the re-election of Mr. Brett Davidson, Mr. D. Brad Paterson, Mr. Dennis Minano, Mr. Steven Percy and Mr. Roger Kazanowski as Directors and the election of Mr. Mark Bernard as a new member of the Board of Directors.

Wavefront Technology Solutions, Inc. (WFTSF), closed Monday's trading session at $1.00, up 3.09%, on 277,975 volume with 137 trades. The average volume for the last 60 days is 24,874 and the stock's 52-week low/high is $0.74/$1.01.

Blue Calypso, Inc. (BCYP)

Ceocast News, Stock Edge, Wall Street Hustler, The Stock Brainiac, Your Stock Alert, StockMister, and Penny Stock SMS Publisher reported earlier on Blue Calypso, Inc. (BCYP), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Based in Dallas, Texas, Blue Calypso, Inc. is a leader in digital word-of-mouth marketing and advertising. The Company has their patented engine and with it, brands can use the power of friend-to-friend referrals through empowering their advocates to share brand content with their unique social graph and rewarding sharing and engagement. Blue Calypso's shares trade on the OTC Markets' OTCQB.

The Company offers their White Label Enterprise Solution. They offer custom branded technology that empowers a brand's advocates to share key promotional messages with all of their friends via mobile and social media. Strong tracking and analytics provide strong insight into customer behavior and influence. Additionally, Blue Calypso has their Proprietary Community. They foster a proprietary community of endorsers within CALYP. This social sharing platform enables consumers to share the brands, businesses and products they love with their friends.

Consumers discover brand content in CALYP. They share their endorsement with their friends through social posts, email, or text messages. In return, they are rewarded with cash from CALYP and benefits from the brand. CALYP is available in the iTunes App Store, Android Market, or online.

This past January, Blue Calypso announced their new product offering called EMGage. The EMGage solution assists companies in leveraging the power of their employees to communicate company messages across social media. EMGage is a fully customized, branded platform. It enables organizations to offer employees the opportunity to distribute national or regional content across multiple social media channels with one click.

The EMGage solution helps organizations empower employees to share key branding and promotional messages with their friends; track the spread of messages and actions taken by friends for attribution, and reward top employee influencers with the brand's currency for helping get the word out. EMGage takes advantage of employee groups to promote their company brand to their peers and subsequently drive growth in the company's social referral activity and sales. Organizations can drive deeper engagement and productivity with employees by way of empowerment and rewards.

Blue Calypso, Inc. (BCYP), closed Monday's trading session at $0.348, even for the day. The average volume for the last 60 days is 10,946 and the stock's 52-week low/high is $0.226/$0.6215.

Global Resource Energy, Inc. (GBEN)

PennyStocks24 and Research Driven Investor reported today on Global Resource Energy, Inc. (GBEN), PickPennyStocks, Michael Stone, Growing Stocks Report, Research Driven Alerts, SmallCapInvestorDaily, PennyStockScholar, OTCtipReporter, Stockdigest Report reported this month, and we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Global Resource Energy, Inc. is a Clean Energy Solutions Company that is working to deliver clean renewable energy worldwide, with an initial focus on North America. The Company's principal focus is to acquire evolving renewable technologies and to deliver reliable, clean energy that is harvested from local sustainable natural resources. They will provide services and solutions to businesses, communities and individuals. The Company lists on the OTCQB. Global Resource Energy has their corporate headquarters in Las Vegas, Nevada.

The Company recently entered into an agreement with a license holder of a major technology that shows significant promise under laboratory conditions. The MyCroft® fuel cell is a 'recirculating loop electric generator' (R-LEG). It utilizes the motion of hydrogen within a sealed loop to create electricity that appears scalable to a vast number of commercial applications. The system is practical and effective; it could undergo development for small-scale (micro power) medical applications. Economies of scale could eventually lead to industrial and residential applications.  

The system has undergone investigation with measured performance documented by researchers from a highly respected research and testing laboratory. Further research and development is underway. Global Resource Energy plans to optimize the management and development of the MyCroft® technology via several funding scenarios.

In January 2013, Global Resource Energy announced the pre-purchase of 66,000 Certified Emission Reduction Credits from BluForest, Inc. The total purchase price of $660,000.00 is to be paid to BluForest in the form of 3,000,000 restricted shares of Global Resource Energy. BluForest is a publicly traded carbon offsets marketing company.

Certified Emission Reductions (CERs) are a type of emissions unit (or carbon credits). They are issued by the Clean Development Mechanism (CDM) Executive Board for emission reductions achieved by CDM projects and verified by a DOE under the rules of the Kyoto Protocol.

Governmental and private entities can hold CERs on electronic accounts with the UN. CERs can be purchased from the primary market (purchased from the original party that makes the reduction) or the secondary market (resold from a marketplace).

Global Resource Energy, Inc. (GBEN), closed Monday's trading session at $0.069, up 10.22%, on 4,596,184 volume with 282 trades. The stock's 52-week low/high is $0.019/$0.0768.

Klondike Silver Corp. (KS.V)

Agoracom reported previously on Klondike Silver Corp. (KS.V), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Listed on the TSX Venture Exchange, Klondike Silver Corp. is a resource exploration stage company that engages in the acquisition and exploration of mineral properties. The Company is reviving historic silver producing districts and exploring a carefully selected portfolio of properties in Canada. Their corporate objective is to rehabilitate and restore the prospective mines to production and to use the cash flow generated to finance advanced exploration technologies to find new discoveries. Incorporated in 2005,  Klondike Silver is based in Vancouver, British Columbia (B.C.).

The Company has a portfolio of silver properties throughout Canada. The most notable is in the historic Slocan Mining District in southeastern B.C.  Klondike Silver is the dominant landholder controlling a majority of the historic camp and the fully permitted, 100 percent owned Sandon Mining Complex. Klondike owns the past-producing Silvana, Wonderful, and Hinckley Mines and numerous other properties with significant exploration potential. The Slocan Project is 50 km northwest of Nelson, B.C.  Minerals at this project are silver, with associated lead and zinc.

In the Yukon, the Company is exploring silver or silver-rich polymetallic projects. The most advanced project is the wholly owned Stumpy Property, 55 km southeast of Ross River and close to the former Ketza River gold mine. Klondike Silver also has their Gowganda Project in the Timiskaming Region, Ontario. This project is 100 percent owned by Klondike Silver and the minerals are silver, with associated cobalt and minor copper and nickel.

Earlier this month, Klondike Silver announced that their underground rehabilitation efforts are advancing well in and around the Silvana mine location. The Company is expecting to gain access to historically productive sites using the same historical records that have allowed them to produce consistently for more than a year. Klondike Silver is using the historical records created during the exploration and mining of the Slocan Mining Camp to locate sources of past producing silver deposits in their underground mining structure.

The Company has recently completed the bypass adit to connect the Silvana mine at the 4625' adit level to the past producing Hope mine to the east. Klondike Silver recently announced that they increased their underground mining operations at the Silvana Mine in the Silver Slocan Mining Camp. They are currently producing at a rate of 40 tons per day via their 100 percent owned Sandon Mining Complex.

Klondike Silver Corp. (KS.V), closed Monday's trading session at $0.65, even for the day. The stock's 52-week low/high is $0.12/$1.01.

DelMar Pharmaceuticals, Inc. (DMPI)

We are highlighting DelMar Pharmaceuticals, Inc. (DMPI) today, here at the QualityStocks Daily Newsletter.

Trading on the OTC Bulletin Board, DelMar Pharmaceuticals, Inc.'s focus is to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. DelMar's lead asset is VAL-083. Currently, it is undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. DelMar Pharmaceuticals is based in Vancouver, British Columbia. The headquarters for their Research & Clinical Trials is in Menlo Park, California.

DelMar takes advantage of existing clinical and commercial data from a broad spectrum of sources. This is to accelerate the Company's development timelines and reduce technical risk. Their product candidate, VAL-083, benefits from an historical investment of over US$50 million by the National Cancer Institute (NCI) in the U.S. The drug is well characterized; it has undergone study in over 40 Phase I and Phase II NCI-sponsored human clinical trials in the U.S. and in Europe.

VAL-083 has approval as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and solid tumors, including lung cancer. Published pre-clinical and clinical data indicate that VAL-083 may be active against an array of tumor types by way of a novel mechanism of action. VAL-083 target markets are the aforementioned Glioblastoma Multiforme (GBM), additional Orphan Drug Indications – AML, as well as Lung Cancer.

At the end of February, DelMar Pharmaceuticals announced the appointment of Mr. John K. Bell to DelMar's Board of Directors. Mr. Bell is Chairman of Onbelay Capital, Inc. Onbelay is a Canadian based private equity Company with principal investments in Telematics and auto parts manufacturing (for the past 5 years). Before that, Mr. Bell was CEO and owner of Polymer Technologies, Inc. from 1996 to 2005. Polymer Technologies is an automotive parts manufacturer.

This month, DelMar Pharmaceuticals announced that they were named to Rocket Builder's 11th annual "Ready to Rocket" list. Rocket Builders "Ready to Rocket" list recognizes British Columbia technology companies that have the best positioning to capitalize on the 2012 technology sector trends that will lead them to faster growth than their peers. According to Rocket Builders, the annual "Ready to Rocket" lists provide accurate predictions of companies that will likely experience significant growth, venture capital investment or acquisition by a major player in the coming year.

DelMar Pharmaceuticals, Inc. (DMPI), closed Monday's trading session at $0.136, up 3.85%, on 815,473 volume with 80 trades. The stock's 52-week low/high is $0.03/$0.45.

Encanto Potash Corp. (ENCTF)

We are highlighting Encanto Potash Corp. (ENCTF), here at the QualityStocks Daily Newsletter.

Encanto Potash Corp. engages in the exploration and development of potash properties in the Province of Saskatchewan, Canada. Through a Joint Venture agreement with Muskowekwan Resources Ltd. (MFN JV) on Encanto's flagship property, the Company has a project land package that totals approximately 61,000 largely contiguous acres. Potash is a major ingredient in most commercial fertilizers, which contain a mix of potassium (K), nitrogen (N) and phosphate (P). Encanto Potash lists on the OTCQX International and on the TSX Venture Exchange under the trading symbol "EPO.V".

Encanto Potash formed to work with First Nations Peoples in Saskatchewan to develop potash resources on their lands. The Company is working with the Muskowekwan, Ochapowace and Chacachas First Nations. Encanto is to explore for potash on their southeastern Saskatchewan properties. These properties are joined by the SPAR property, which is located on Provincial lands. Encanto Potash is conducting their Feasibility Study, including bridge engineering, and infrastructure planning necessary for production.

The NI 43-101 Report on the Spar Property estimates a total indicated resource of 12.49 million tonnes of K2O and an inferred resource of 12.24 million tonnes of K2O. There are more than 180,000-acres of potash claims in the Prairie Evaporite Formation. Encanto is currently undertaking a 2-D seismic program on this Property. Encanto has a 100 percent interest in the 91,550-acre Spar property. The Company also has a 100 percent interest in the 55,000-acre Ochapowace/Chacachas property.

Encanto Potash and their Muskowekwan First Nations Partner have developed recoverable KCI potash resources of 130.7 million tonnes of Measured and Indicated (M&I) and 234.7 million tonnes of Inferred on their lands. The Company's 100 percent interest in the Muskowekwan Potash Property covers acreage on the Muskowekwan First Nation Lands. A Pre-Feasibility Study was released in February 2013 confirming Proven & Probable KCI Reserves totaling 162 MMt grading 28 percent. This supports primary and secondary mining for more than 50 years at an annual rate of 2.8 million tonnes. At present, the Company is exploring domestic and international strategic partnerships for the financing, development and sale of potash production from their Muskowekwan JV Property.

Yesterday, Encanto Potash announced that Dr. Simon Desjardins was appointed to the role of Vice President of Technical Services and Project Management and Mr. Darren Svedahl joined the Encanto team as Manager, Lands and Government Relations. Dr. Desjardins previously worked at Alderon Iron Ore Corp; he was responsible for port terminal management and procurement of long lead-time production items. Mr. Svedahl has 20 years experience working with the Canadian Federal government in the departments of Natural Resources Canada (NRCan) and Aboriginal Affairs and Northern Development Canada (AANDC). His most recent position was Manager of Lands and Environment for AANDC's Saskatchewan Region.

Encanto Potash Corp. (ENCTF), closed Monday's trading session at $0.038, down 24.00%, on 33,300 volume with 5 trades. The stock's 52-week low/high is $0.015/$0.45.

Globalstar, Inc. (GSAT)

The Bull Report, Wall Street Wolves, Smart Penny Stocks, Stock Analyzer, and PennyTrader Publisher reported earlier on Globalstar, Inc. (GSAT), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.

Established in 2003, Globalstar, Inc. is a foremost provider of mobile satellite voice and data services. The Company offers these services to commercial and recreational users in over 120 countries globally. Worldwide customer divisions include oil and gas, government, mining, forestry, commercial fishing, utilities, military, transportation, heavy construction, emergency preparedness, business continuity, and individual recreational users. Globalstar has their corporate headquarters in Covington, Louisiana.

Their products include mobile and fixed satellite telephones, simplex and duplex satellite data modems, and flexible service packages. The Company's data solutions are suited for diverse asset and personal tracking, data monitoring and SCADA applications.

On October 19, 2010, Globalstar began launching their second-generation satellite constellation designed to restore their industry leading commercial voice and duplex data services. Globalstar successfully launched their final group of second-generation satellites on February 6, 2013. Upon being placed in service, Globalstar will have positioning as the first mobile satellite services provider to complete the deployment of a second-generation constellation of low-earth-orbit (LEO) satellites.

Since October 1, 2012, Globalstar has completed the initial in-orbit systems performance review for all satellites launched in February. The Company placed the first two satellites into commercial service this month. The expectation is that the remaining satellites will be placed into service over the next few months.

This month, Globalstar announced the signing of a three-year manufacturing, airtime, and distribution agreement with Nupoint Systems. This agreement is to expand the Company's M2M data communication service offerings beyond the reach of terrestrial (cellular) communication. Nupoint Systems' products and services integrated with Globalstar satellite data services will be used to provide two-way communications for M2M data collection and monitoring of customer assets.

Globalstar also announced this month their 2012 Fourth Quarter and Annual Results. Financial highlights include year-over-year Adjusted EBITDA improving by $16.2 million. Total revenue increased 10 percent in the fourth quarter and 5 percent in 2012 from year ago periods. Revenue was $19.1 million for the fourth quarter of 2012 compared to $17.4 million for the fourth quarter of 2011. Revenue increased to $76.3 million during 2012, in comparison to $72.8 million for 2011.

Globalstar reported a net loss of $19.0 million for the three months ended December 31, 2012, in comparison to a net loss of $33.7 million for the fourth quarter of 2011. Their net loss increased $57.3 million during 2012 to $112.2 million. This was mainly due to non-cash items, including a reduction in derivative gains and an increase in depreciation expense, and an accrual for a contract termination charge and an increase in interest expense.

Globalstar, Inc. (GSAT), closed Monday's trading session at $0.98, up 1.03%, on 21,040 volume. The stock's 52-week low/high is $0.58/$2.85.


The QualityStocks
Company Corner


Rainbow Coral Corp. (RBCC)

The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.13, up 6.25%, on 206,565 volume with 43 trades. The stock’s average daily volume over the past 60 days is 145,359, and its 52-week low/high is $0.145/$2.67.

Rainbow Coral Corp. took some time today to go over steps being taken by the company's biotech subsidiary, Rainbow BioSciences, to ensure that the joint venture agreement signed just days ago with major drug delivery innovator TheraKine will realize the full licensing potential of planned drug delivery protocol roll outs. RBCC is hard at work on new targets who would benefit from relevant licenses and is eager to carve out a niche of the global drug delivery market, whose 10 most popular technologies alone could swell to over $81B by 2015.

Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.

Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.

The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.

The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer

Rainbow Coral Corp. Company Blog

Rainbow Coral Corp. News:

RBCC TheraKine Joint Venture Offers Significant Opportunity in Licensing

RBCC Forms Joint Venture With Cutting-Edge Drug Delivery Company TheraKine

RBCC Tech Innovations Drive Big Growth in $60 Billion Drug Delivery Market

Advaxis, Inc. (ADXS)

The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.0888, up 0.91%, on 904,054 volume with 53 trades. The stock’s average daily volume over the past 60 days is 4,664,761, and its 52-week low/high is $0.0275/$0.155.

Advaxis, Inc. announced acceptance of an abstract for oral presentation today entitled “Early Therapeutic Cancer Vaccine Clinical Trial Development," which will be delivered at the upcoming Cancer Immunotherapy Clinical Trials: Concepts and Challenges workshop being held April 4-5, 2013 at the National Institutes of Health Campus (Masur Auditorium) in Bethesda, MD. This major industry workshop held by The Society for Immunotherapy of Cancer will be great exposure and Dr. Robert Petit, VP of Clinical Development and Medical Affairs for ADXS will go over the company's experience in introducing Lm-LLO immunotherapy in a global clinical trial setting Thursday, April 4 at 10:30 am during Session 1 of the workshop.

Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer

Advaxis, Inc. Company Blog

Advaxis, Inc. News:

Advaxis Announces Abstract Accepted for Oral Presentation at SITC Cancer Immunotherapy Clinical Trials Workshop

Advaxis Nominated for Best Early-Stage Vaccine Biotech at 6th Annual Vaccine Industry Excellence Awards

Advaxis’ ADXS-cHER2 Immunotherapy Researchers Receive Penn One Health Award for Initiatives in Canine Osteosarcoma


The QualityStocks Daily Newsletter would like to spotlight VIASPACE, Inc. (VSPC). Today, VIASPACE, Inc. closed trading at $0.015, up 0.67%, on 756,991 volume with 22 trades. The stock’s average daily volume over the past 30 days is 1,250,000, and its 52-week low/high is $0.0013/$0.0158.

Viaspace, Inc. announced an additional 90 day lock-up (through June 30) of common shares held by the company's board today, including those of Chairman, Dr. Kevin Schewe, CEO, Dr. Kukkonen, and Angelina Galiteva. Company CFO, Stephen Muzi, as well as Director of communications, Dr. Jan Vandersande, and Social Media Outreach Director, Jaclyn Kenner, have also agreed to take part, effectively extending the quantity to 240M shares that will not be sold during the extension. This move to lock-up shares, in the midst of corporate progress and continued momentum, will allow for improved focus on expanding the general shareholder base as CEO Dr. Kukkonen takes two trips in April related to major upcoming news.

VIASPACE, Inc. (VSPC) is focused on growing renewable Giant King™ Grass as a low-carbon fuel for clean electricity generation and environmentally friendly energy pellets, as well as a feedstock for bio-methane production, green cellulosic biofuels, biochemical, and biomaterials. A high-yield, low-cost feedstock, Giant King Grass meets the cost targets of green energy applications while maintaining a carbon neutral profile.

The highest yielding biomass crop in the world, Giant King Grass can grow in a variety of soil conditions and does not compete with food crops. Once Giant King Grass is established, it can be harvested at 3-5 feet tall every 45 to 60 days or at 14 feet tall twice a year. This incredibly high rate of growth provides a continual supply of biomass year-round, enabling strategically located power plants to operate 24 hours a day regardless of the current season.

VIASPACE provides Giant King™ Grass seedlings and technical expertise to qualified projects. The company also plans to serve as a project developer or co-developer for power plant or pellet mill projects, together with local partners that have land and require electricity, heat, pellets, biogas, or biofuels. VIASPACE and its partners are capable of delivering an integrated Giant King Grass plantation and biomass power plant project in just 24 months.

The excellent energy characteristics of Giant King Grass and its ability to be harvested multiple times each year enable and energy output yield that is much higher than other crops . This superior feedstock offers material productivity benefits at remarkable costs for energy production, biofuels, and biomaterials. Giant King Grass is currently being grown in the United States, Virgin Islands, China, and other areas. Disclaimer

VIASPACE, Inc. Company Blog

VIASPACE, Inc. News:

VIASPACE Insiders Extend Lock-up of Shares

VIASPACE Chairman Interviews with CEONEWS.Tv Regarding Business Dynamics and Recent Corporate Milestones

VIASPACE Announces Contract With AGRICORP And Giant King Grass Growing In Nicaragua

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.26, on 138,151 volume with 52 trades. The stock’s average daily volume over the past 30 days is 150,170, and its 52-week low/high is $0.161/$0.5925.

International Stem Cell Corp. announced an upcoming conference call today to be hosted by Exec. VP, Dr. Simon Craw, in conjunction with the company's CFO, Ms. Linh Nguyen, this March 28, at 11:00 a.m. ET. The call will focus primarily on financial results for the year ended Dec 31, 2012, as well as a business update. The Conference Line (U.S.) is 1-877-941-2068 and the Conference ID is 4610666. The Webcast will be at the following url: http://public.viavid.com/player/index.php?id=104040.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corp. to Host Conference Call Thursday, March 28 to Discuss Year End 2012 Financial Results and Provide Business Update

International Stem Cell Corp. to Host Conference Call on Friday, March 22 to Discuss Positive Study Data of Parkinson's Disease

International Stem Cell Corporation Announces Positive Results of Primate Parkinson's Study

Rainbow Coral Corp. (RBCC) Shares Excitement as TheraKine Joint Venture Moves Forward

Rainbow Coral this morning told investors that it is already searching for new targets that would benefit from adding licenses for the drug delivery protocols TheraKine and RBCC plan to roll out. TheraKline, developer of a revolutionary drug delivery platform that could soon make local delivery of biologic agents and small molecules safer and more effective, joint ventured with RBCC’s biotech subsidiary very recently.

As noted in today’s press release, the global market for drug delivery technologies is driven by biologics and medications that can’t be administered effectively through traditional means. It is believed by some experts that the worldwide market for the 10 most popular drug delivery technologies alone could grow to $81.5 billion in just two years.

Working hard to maximize the success of its latest partnership, RBCC is seeking out healthcare providers for whom TheraKine’s advanced sustained-release delivery system could yield significant returns for their clients. TheraKine has developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.

“Licensing this incredible new platform is going to be one of the key opportunities to making this a successful partnership,” stated RBCC CEO Patrick Brown. “It’s a top priority for our company moving forward. The potential is limitless.”

For more information on RBCC’s initiatives, visit www.rainbowbiosciences.com

Advaxis, Inc. (ADXS) to Present at SITC Cancer Immunotherapy Clinical Trials Workshop

Advaxis, a leading developer of the next generation of immunotherapies for cancer and infectious diseases, announced today that an abstract has been accepted for oral presentation at The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Clinical Trials: Concepts and Challenges workshop being held next week at the National Institutes of Health Campus (Masur Auditorium) in Bethesda, MD.

The abstract titled “Early Therapeutic Cancer Vaccine Clinical Trial Development” will be presented on April 4 at 10:30 am during Session 1 by Dr. Robert Petit, VP of Clinical Development and Medical Affairs at Advaxis. Dr. Petit will describe Advaxis’ experience with conducting early clinical trials with therapeutic Lm-LLO immunotherapies.

“The selection of our abstract for presentation at SITC provides an opportunity for Advaxis to share our experience in introducing Lm-LLO immunotherapy in a global clinical trial setting where there is great medical need,” stated Dr. Petit. “We are working toward a future when immunotherapy can fully take its place alongside conventional treatments in the global battle against cancer.”

For more information, visit www.advaxis.com

VIASPACE, Inc. (VSPC) Insiders Extend Lock-up of Shares

Today before the opening bell, VIASPACE announced that its Board of Directors agreed to extend the lock-up of their VIASPACE common stock shares for an additional 90 days, through June 30, 2013. VIASPACE CFO, Mr. Stephen Muzi; Director of Communications, Dr. Jan Vandersande; and Director of Social Media Outreach, Ms. Jaclyn Kenner, also decided to lock-up their VSPC common shares through June 30, 2013. The approximate number of shares involved in the lock-up extension totals 240,000,000.

“The VIASPACE Board and Management have been extremely pleased with the performance of VIASPACE since becoming a free-standing company on October 1, 2012,” stated Dr. Schewe. “At that time, we announced a 6-month lock-up of insider share sales. Given the pace of our corporate progress and the momentum that we have achieved, we felt it important to continue the lock-up for another 90 days as we work hard to continue to increase the scope of our general shareholder base of investors. In addition, Dr. Kukkonen has two significant foreign trips to meet with clients in April and we are looking forward to sharing the news of those trips and providing exciting updates on existing projects in the near future.”

For more information, visit www.viaspace.com

International Stem Cell Corp. (ISCO) Schedules Conference Call to Discuss Financial Results and Update Investors

International Stem Cell Corp., a biotechnology company specializing in the therapeutic applications of human parthenogenetic stem cells (hpSCs), today announced that it will be hosting a conference call this week to discuss its 2012 financial results as well as provide a business update.

Dr. Simon Craw, Executive Vice President, and Ms. Linh Nguyen, Chief Financial Officer of International Stem Cell, will host the conference call. Those who wish to participate should use the dial-in information below.

Date: Thursday March 28, 2013
Time: 11:00 a.m. ET
Conference Line (U.S.): 1-877-941-2068
International Dial-In: 1-480-629-9712
Conference ID: 4610666
Webcast: http://public.viavid.com/player/index.php?id=104040

ISCO recommends logging in at least 10 minutes before the call start time. A playback of the call will be available shortly after its conclusion. Replay information can be found below.

Teleconference Replay Details:
US Domestic: 1-877-870-5176
International: 1-858-384-5517
Conference ID: 4610666

To learn more about International Stem Cell Corp., visit www.internationalstemcell.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Wall Street Resources





By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251